Iparomlimab and Tuvonralimab Clinical Trials
6 recruitingDrug
Phase 26
Showing 1–6 of 6 trials
Recruiting
Phase 2
Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer
Gastric Cancer Adenocarcinoma Metastatic
Dai, Guanghai68 enrolled1 locationNCT07392346
Recruiting
Phase 2
Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial
Nasopharyngeal Carcinoma (NPC)First-line Treatment Failure Nasopharyngeal Carcinoma
Sun Yat-sen University41 enrolled1 locationNCT07101744
Recruiting
Phase 2
Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
BRAF V600 Colorectal Cancer
Sun Yat-sen University20 enrolled1 locationNCT07150247
Recruiting
Phase 2
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
Neoadjuvant TherapyRadiotherapyImmunotherapy+2 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University40 enrolled1 locationNCT07165847
Recruiting
Phase 2
Iparomlimab and Tuvonralimab in HNSCC
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University30 enrolled1 locationNCT07090317
Recruiting
Phase 2
Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer
Cervical CancerOligometastaticNeoplasm Recurrence, Local
Shandong Cancer Hospital and Institute36 enrolled1 locationNCT06942416